flow semaglutide trial FLOW-Trial-Shadow Semaglutide 1.0 mg (Ozempic) Reduced

Gul U et al

Scientists roughly divide the body into fat mass and lean body mass (LBM)

[DOI] [PubMed] [Google Scholar] Bollag RJ, Zhong Q, Ding KH, Phillips P, Zhong L, Qin F, Cranford J, Mulloy AL, Cameron R, Isales CM

Clinical trials have demonstrated significant weight loss in individuals taking Semaglutide compared to those on a placebo

Individual cardiac history, current medications, disease severity, and specific contraindications all factor into this clinical decision

For uninsured patients, combining genetic context with clinical biomarkers (glucose, lipids, inflammatory markers) and a thorough provider assessment can transform cost-conscious decision-making from guesswork into a structured, personalized pathway